While SGLT2 inhibitors offer significant benefits and show great promise in their multifaceted approach to the management of T2DM and heart failure by virtue of their cardiovascular benefits, they have the potential to cause rare adverse effects, most notably, in some cases, pancreatitis. This evidence concerns the gene SLC5A2 and pancreatitis.